ReviewGut and liver2022
Postinfection Irritable Bowel Syndrome.
Review in Gut and liver, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Risk factors for developing irritable bowel syndrome: systematic umbrella review of reviews.BMC medicine · 2025Pooled it
- Modern concepts of small intestinal bacterial overgrowth.Current opinion in gastroenterology · 2025Review
- Though systemic inflammatory markers may remain elevated after recovery from coronavirus disease-19, gut mucosal inflammation resolves soon after recovery.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Post-infectious irritable bowel syndrome in a paediatric population: first data in a Middle Eastern country.BMC pediatrics · 2025Article
- Atractylenolide I ameliorates post-infectious irritable bowel syndrome by inhibiting the polymerase I and transcript release factor and c-Jun N-terminal kinase/inducible nitric oxide synthase pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Gut microbiota in irritable bowel syndrome: a narrative review of mechanisms and microbiome-based therapies.Frontiers in immunology · 2025Review
- Causal Relationships of Chronic Constipation and Irritable Bowel Syndrome with Digestive Tract Cancers: A Mendelian Randomization Study.Recent patents on anti-cancer drug discovery · 2025Article
- Leaky Gut Syndrome: Myths and Management.Gastroenterology & hepatology · 2024Article
- Epidemiology of Disorders of the Gut-Brain Interaction: An Appraisal of the Rome IV Criteria and Beyond.Gut and liver · 2024Review
- Role of autoantibodies in the pathophysiology of irritable bowel syndrome: a review.Frontiers in physiology · 2024Review
- Association between ideal cardiovascular health and bowel conditions among US adults.Frontiers in nutrition · 2024Article
- Post-COVID-19 and Irritable Bowel Syndrome: A Literature Review.Medicina (Kaunas, Lithuania) · 2023Review
- Chlorogenic Acid Ameliorates Post-Infectious Irritable Bowel Syndrome by Regulating Extracellular Vesicles of Gut Microbes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Post-infection functional gastrointestinal disorders following coronavirus disease-19: a prospective follow-up cohort study.BMC infectious diseases · 2023Article
- Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review.World journal of gastroenterology · 2023Review
- Low FODMAP Diet Relieves Visceral Hypersensitivity and Is Associated with Changes in Colonic Microcirculation in Water Avoidance Mice Model.Nutrients · 2023Article
- Post-infection functional gastrointestinal disorders following coronavirus disease-19: A case-control study.Journal of gastroenterology and hepatology · 2022Article
- Chronic pain and infection: mechanisms, causes, conditions, treatments, and controversies.BMJ medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following acute gastroenteritis (AGE) due to bacteria, viruses, or protozoa, a subset of patients develop new onset Rome criteria positive irritable bowel syndrome (IBS), called postinfection IBS (PI-IBS). The pooled prevalence of PI-IBS following AGE was 11.5%. PI-IBS is the best natural model that suggests that a subset of patients with IBS may have an organic basis. Several factors are associated with a greater risk of development of PI-IBS following AGE including female sex, younger age, smoking, severity of AGE, abdominal pain, bleeding per rectum, treatment with antibiotics, anxiety, depression, somatization, neuroticism, recent adverse life events, hypochondriasis, extroversion, negative illness beliefs, history of stress, sleep disturbance, and family history of functional gastrointestinal disorders (FGIDs), currently called disorder of gut-brain interaction. Most patients with PI-IBS present with either diarrhea-predominant IBS or the mixed subtype of IBS, and overlap with other FGIDs, such as functional dyspepsia is common. The drugs used to treat non-constipation IBS may also be useful in PI-IBS treatment. Since randomized controlled trials on the efficacy of drugs to treat PI-IBS are rare, more studies are needed on this issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.